摘要
神经退行性疾病的一个共同特征是以酶抗性的蛋白质为主的错误折叠的形成。根据当前神经退行性疾病的理念这些物质可以形成有毒的组件。错折叠蛋白的重叠是这些疾病的典型特征。错折叠蛋白和有毒的聚集体的形成指向这些疾病的共同途径:ER应激和线粒体能量产生导致ER中正常蛋白质折叠的障碍。阿尔茨海默氏病(AD)是一种相当异质的,多因素疾病,其具有广泛的临床异质性,并且被分类成若干亚型。在AD中的淀粉样前体蛋白(APP)和有毒的β淀粉(Aβ)的结构的形成是非正常的。Aβ同时影响ER和线粒体,扰乱细胞的钙离子内稳态。线粒体功能障碍是AD的主要病理环节之一。线粒体积累来自ER /高尔基体或从相关的线粒体的ER-膜(MAM)衍生的Aβ。线粒体中自由基,氧化应激和增加钙-浓度使ATP的产生减少。由于Aβ的毒性线粒体动态和转运也被改变。突触线粒体表现出了非常高的隐患。钙水平在ER导致蛋白质折叠的功能障碍最终激活了折叠蛋白应答(UPR),并且还影响线粒体。MAM可以在ER线粒体交互中发挥特殊的作用。线粒体本身(使用线粒体靶向抗氧化剂如的MitoQ)可能是AD治疗一个特殊的目标。另一个目标是UPR级联蛋白(PERK、IRE1、ATF6)和ER(兰尼、IP3R)的参与稳定钙水平的受体。
关键词: β淀粉样蛋白,内质网,线粒体相关内质网膜,线粒体故障,突触线粒体,折叠蛋白应答。
Current Alzheimer Research
Title:Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Volume: 12 Issue: 7
Author(s): Katalin Volgyi, Gábor Juhász, Zsolt Kovacs and Botond Penke
Affiliation:
关键词: β淀粉样蛋白,内质网,线粒体相关内质网膜,线粒体故障,突触线粒体,折叠蛋白应答。
摘要: A common feature of neurodegenerative diseases is the formation of misfolded, mostly enzyme resistant proteins. These substances may form toxic assemblies according to the current concept of the neurodegenerative diseases. Overlapping of the misfolded proteins is typical in these disorders. The formation of misfolded proteins and toxic aggregates point to a common pathway of these disorders: failure in normal protein folding in the ER as a consequence of ER-stress and mitochondrial energy production. Alzheimer's disease (AD) is a rather heterogeneous, multifactorial disorder with wide clinical heterogeneity and is classified into several subtypes. In AD the processing of the amyloid precursor protein (APP) and formation of toxic β-amyloid (Aβ) structures occur intraneuronally. Aβ affects both ER and mitochondria and disturbs Ca2+-homeostasis of the cells. Mitochondrial dysfunction is one of the main pathological events in AD. Mitochondria accumulate Aβ derived from the ER/Golgi or from the mitochondriaassociated ER-membranes (MAM). Free radicals, oxidative stress and increasing Ca2+-concentration in mitochondria cause decreased ATP production. Mitochondrial dynamic and trafficking are also altered as a result of Aβ toxicity. Synaptic mitochondria show a very high vulnerability. Depletion of Ca2+ level in the ER results in dysfunction of protein folding and evokes unfolded protein response (UPR), and affects also mitochondria. MAM may play special role in the ERmitochondria cross talk. Mitochondria themselves (using mitochondria-targeting antioxidants such as MitoQ) could be a special target for AD treatment. Another targets are the UPR cascade proteins (PERK, IRE1, ATF6) and receptors involved in Ca2+ -level stabilization of the ER (Ryr, IP3R).
Export Options
About this article
Cite this article as:
Katalin Volgyi, Gábor Juhász, Zsolt Kovacs and Botond Penke , Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk, Current Alzheimer Research 2015; 12 (7) . https://dx.doi.org/10.2174/1567205012666150710095035
DOI https://dx.doi.org/10.2174/1567205012666150710095035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Neglected Aspects of Drug Discovery - Microbiological Aspects
Current Clinical Pharmacology Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Muscarinic Acetylcholine Receptors: New Potential Therapeutic Targets in Antinociception and in Cancer Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy S100b Induces Expression of Myoglobin in APβ Treated Neuronal Cells In Vitro: A Possible Neuroprotective Mechanism
Current Aging Science Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews